Navigation Links
Molecular Devices Returns to Life Sciences Marketplace

SUNNYVALE, Calif., Feb. 3 /PRNewswire/ -- Today, Molecular Devices, Inc.—now part of Danaher Corporation—re-launched the Molecular Devices brand into the life sciences marketplace. The renewed corporate brand is focused primarily on meeting customer needs and exceeding customer expectations, and includes an evolved visual identity system. A new logo illustrates the company's commitment to provide high-performance analytical technologies that support the scientific success of its customers: the company's instrument—the customer's biology.

First introduced more than 25 years ago, the Molecular Devices brand has earned increasing value in life sciences markets, becoming a well-recognized and sought-after brand for analytical instrumentation. Now, as part of the Danaher Medical Technologies segment, Molecular Devices, Inc. is focused on renewing its brand, seeking to retain and rebuild many of its historical attributes while adding new ones that translate into direct value for customers.

"Our employees are excited about a new Molecular Devices brand that is focused primarily on serving our customers to the best of our abilities," said Tom Olenic, Vice President and General Manager for Molecular Devices, Inc. "The acquisition has given us a chance to take a close look at the way we do business and, in doing so, to identify the way we could be doing business—it's a tremendous opportunity, and we are definitely taking full advantage of it."

Going forward, Molecular Devices will have a singular focus—its customers. Whether a long-time user, recent adopter, or prospective customer, their needs will fuel the company's actions. By hiring and retaining creative, best-in-class people, Molecular Devices will continue to design, manufacture, and commercialize analytical instruments, software, and assays to support the scientific success of its customers, regardless of objective: publication, compound hits, lead compounds, new molecular entity, bioassay, biotest, etc. The company will also provide dedicated, follow-on support to ensure that customer needs and expectations continue to be met over time.

According to Tom Driscoll, Vice President of Global Marketing for Molecular Devices, Inc., "Understanding each customer's unique laboratory workflow continues to be a top priority, and we will direct product development efforts toward solving customer issues and optimizing customer workflows. Our goal now, as a new Molecular Devices brand, is to deliver highly relevant analytical products and services to detect biology, decode data, and drive successful life science discovery in both applied and basic research environments."

Today, the Molecular Devices brand includes specialized products, services, and expertise for microplate, microarray, and label-free analysis; high-content and research imaging; automated and conventional electrophysiology; cellular screening; laser capture microdissection; and contaminant detection. Its products offer a full range of detection technologies and can meet all throughput needs to help drive success in basic research—from molecular to cellular to systems biology—as well as applied research—from discovery to development to production of new drugs, vaccines, and tests.

Some of the business' top product brands, which will also undergo renewal this year, include: SpectraMax®, ImageXpress®, Axon™, IonWorks®, Threshold®, CellKey™, FLIPR®, and Arcturus®.

About Molecular Devices, Inc.

Founded in 1983, Molecular Devices Corporation introduced its first microplate reader in 1987 and has continually broadened its product and service portfolio through a combination of internal research and development and strategic acquisitions, including Universal Imaging Corporation (2002), Axon Instruments (2004), and Blueshift Biotechnologies, Inc. (2006). In 2007, Molecular Devices Corporation was acquired by MDS Inc. and integrated into its MDS Analytical Technologies division. And, in 2010, the business was acquired by Danaher Corporation and now operates independently as part of its Medical Technologies segment. Molecular Devices, Inc. designs, develops, and commercializes high-performance analytical instruments, software, and reagents to help drive success in basic life sciences research, drug discovery, biologics development and production, and bioassay and biotest development. The business is in the process of returning a renewed, independent Molecular Devices brand to the life sciences marketplace, with a focus on delivering unique value to customers. More information can be found at

Molecular Devices®, the Molecular Devices logo, SpectraMax®, ImageXpress®, Axon™, IonWorks®, Threshold®, CellKey™, FLIPR®, Arcturus®, and all other trademarks are the property of Molecular Devices, Inc.

SOURCE Molecular Devices, Inc.



SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
2. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
3. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
4. Data From Three Clinical Studies of bioTheranostics Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
5. Reportlinker Adds Molecular Diagnostics - A World Market Review
6. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
7. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
8. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
9. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. Ionian Technologies, Inc. Signs Molecular Diagnostic Manufacturing Agreement With Roche Diagnostics
11. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
Post Your Comments:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):